English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

A patient presenting with concomitant epidermal growth factor receptor ( EGFR)  mutation and anaplastic lymphoma kinase ( ALK)  translocation is rare. We report a non‐small cell lung cancer ( NSCLC)  patient with concomitant  ALK  rearrangement and exon 19 ( E746‐A750del )  EGFR  mutation. The  ALK  rearrangement was confirmed not only in the primary tumor biopsy specimen, but also in the pleural effusion cell block by reverse transcriptase‐polymerase chain reaction ( RT‐PCR) ,  V entana  ALK  immunohistochemistry assay, and fluorescence in situ hybridization. No clinical benefit using chemotherapy or  EGFR  tyrosine kinase inhibitor gefitinib was obtained in this case.

thoracic cancer

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement